TVTX
HealthcareTravere Therapeutics, Inc. · Biotechnology · $4B
What is Travere Therapeutics, Inc.?
Travere Therapeutics is a San Diego-based biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases. The company targets conditions with limited treatment options, serving both pediatric and adult patient populations.
Travere generates revenue through a portfolio of marketed rare-disease therapies while advancing a clinical pipeline targeting kidney and metabolic disorders. The company sells approved treatments for conditions including bile acid synthesis disorders and cystinuria, and is advancing late-stage candidates for kidney diseases such as IgA nephropathy and focal segmental glomerulosclerosis. Partnerships with the National Institutes of Health and patient advocacy groups support early-stage research into additional rare conditions.
Incorporated in 2008 and operating under its current name since November 2020, Travere Therapeutics is headquartered in San Diego, California.
- Chenodal — oral therapy for radiolucent gallbladder stones
- Cholbam — cholic acid capsules for bile acid synthesis disorders
- Thiola and Thiola EC — tiopronin tablets for cystinuria
- Sparsentan — Phase III candidate for IgA nephropathy and FSGS
- TVT-058 — investigational enzyme replacement for classical homocystinuria
Is TVTX a Good Stock to Buy?
UQS Score rates TVTX as Below Average overall, reflecting meaningful trade-offs across its five quality pillars.
The Growth pillar stands out as the clearest bright spot in TVTX's profile, driven by the commercial trajectory of its rare-disease portfolio and the potential of its late-stage pipeline. The Moat pillar registers as Neutral, reflecting the niche positioning that rare-disease franchises can provide through orphan drug designations and limited competition.
The Quality and Risk pillars both score Weak, signaling concerns around financial durability and the inherent uncertainty of a biotech still scaling its commercial operations alongside an active clinical pipeline.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does TVTX pay dividends?
No — Travere Therapeutics, Inc. does not currently pay a dividend.
Travere Therapeutics does not currently pay a dividend. This is typical for clinical-stage and early-commercial biopharmaceutical companies, which generally reinvest available capital into research, development, and commercialization efforts rather than returning cash to shareholders. Investors in TVTX are primarily seeking growth from pipeline milestones and revenue expansion rather than income.
When does TVTX report earnings?
Travere Therapeutics reports earnings on a quarterly cadence, consistent with standard practice for US-listed public companies.
Quarterly results for rare-disease biotechs like Travere tend to reflect both commercial product revenues and ongoing pipeline investment costs. Investors typically watch for updates on Sparsentan's regulatory and commercial progress alongside overall revenue trends from the marketed portfolio.
For the most recent quarter's results and guidance, visit Travere Therapeutics' investor relations page directly.
TVTX Price History
+155.6% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Travere Therapeutics, Inc.?
Based on Travere Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
TVTX Long-term Outlook
The UQS Growth pillar for TVTX is rated Strong, suggesting the company's revenue trajectory is among the more compelling aspects of its profile. However, the Weak Risk pillar tempers the outlook — pipeline-dependent biotechs carry binary event risk, and the path to sustained profitability remains a key variable. The Neutral Valuation pillar indicates the market is pricing in a balanced mix of opportunity and uncertainty at current levels.
Growth drivers
- Potential regulatory approval and commercial launch of Sparsentan in IgA nephropathy
- Continued growth of the existing rare-disease commercial portfolio
- Expansion into additional rare conditions through NIH partnerships and early-stage research
Key risks
- Clinical trial failure or regulatory setbacks for pipeline candidates
- High operating costs relative to current revenue scale
- Competitive pressure in rare kidney disease from larger biopharmaceutical players
TVTX vs Peers
Travere operates in the rare-disease and specialty biopharmaceutical space alongside several focused peers.
ACADIA focuses on central nervous system rare diseases, giving it a distinct therapeutic focus compared to Travere's kidney and metabolic disease orientation.
Edgewise is a clinical-stage company targeting muscle diseases, representing an earlier-stage rare-disease model relative to Travere's mixed commercial and pipeline profile.
Telix specializes in radiopharmaceuticals for oncology and urology, differentiating itself from Travere through its imaging and therapeutic isotope platform.
Frequently Asked Questions
What does Travere Therapeutics do?
Travere Therapeutics is a biopharmaceutical company focused on rare diseases. It markets approved therapies for conditions including bile acid synthesis disorders and cystinuria, while advancing a clinical pipeline targeting rare kidney diseases. The company also collaborates with the National Institutes of Health on early-stage rare disease research.
Does TVTX pay dividends?
Travere Therapeutics does not currently pay a dividend. Like most clinical-stage and early-commercial biotechs, the company reinvests capital into research, development, and commercialization rather than distributing cash to shareholders.
When does TVTX report earnings?
Travere Therapeutics follows a standard quarterly earnings cadence for US-listed companies. For specific dates and the most recent financial results, check the investor relations section of the company's official website.
Is TVTX a good stock to buy?
UQS Score rates TVTX as Below Average overall. The Growth pillar is rated Strong, but the Quality and Risk pillars are both Weak, reflecting the financial and clinical uncertainties common to rare-disease biotechs at this stage. The full pillar breakdown is available to UQS Pro members.
Is TVTX overvalued?
The UQS Valuation pillar for TVTX is rated Neutral, suggesting the market is pricing the stock in a balanced range relative to its fundamentals. Rare-disease biotechs often carry valuation premiums tied to pipeline potential, and that dynamic appears reflected in the current assessment.
How does TVTX compare to its competitors?
Travere competes in the rare-disease space alongside companies like ACADIA Pharmaceuticals, Edgewise Therapeutics, and Telix Pharmaceuticals. Each focuses on different therapeutic areas — CNS, muscle disease, and radiopharmaceuticals respectively — making direct comparisons nuanced. UQS Pro members can view side-by-side pillar scores for a structured comparison.
What is TVTX's market cap bracket?
Travere Therapeutics is classified as a mid-cap company. This places it in a segment that often balances some commercial scale with meaningful growth potential, though mid-cap biotechs can carry higher volatility than large-cap pharmaceutical peers.
Who founded Travere Therapeutics?
The company was originally incorporated in 2008 under the name Retrophin, Inc. It rebranded to Travere Therapeutics in November 2020. Founding and leadership history is publicly available through the company's official filings and investor relations materials.
Is TVTX a long-term quality investment?
From a long-term quality perspective, TVTX's UQS profile presents a mixed picture. The Strong Growth pillar suggests meaningful revenue potential, but Weak Quality and Risk scores indicate the company has not yet demonstrated the financial consistency typically associated with durable long-term holdings. Pro members can explore the full analysis to assess fit for their own criteria.
What is the main competitive advantage of Travere Therapeutics?
Travere's focus on rare diseases provides a degree of natural insulation from broad competition. Orphan drug designations, small patient populations, and specialized clinical expertise create barriers that larger pharmaceutical companies may not prioritize. The UQS Moat pillar rates this positioning as Neutral — present, but not yet deeply entrenched.
What sector does TVTX belong to?
Travere Therapeutics operates in the Healthcare sector, specifically within the rare-disease and specialty biopharmaceutical segment. Investors can explore other [top Healthcare stocks](/sector/healthcare) on UQS Score to see how TVTX fits within the broader sector landscape.
Unlock Full TVTX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare TVTX side-by-side with rare-disease peers
- ✓Screen for high-quality biotech stocks by pillar
- ✓Get the full risk and valuation deep-dive
Pro Analysis
TVTX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | 45.6 | 17.6 | 45.0 | 100.0 | 23.5 | 42.7 | 0.0 |
| May 19, 2026 | 45.6 | 17.6 | 45.0 | 100.0 | 23.5 | 43.0 | +0.2 |
| May 14, 2026 | 45.4 | 17.5 | 45.0 | 100.0 | 23.5 | 41.6 | -0.1 |
| May 11, 2026 | 45.5 | 17.6 | 45.0 | 100.0 | 23.5 | 42.4 | -2.8 |
| May 8, 2026 | 48.3 | 0.0 | 45.0 | 100.0 | 36.9 | 77.0 | +3.2 |
| May 7, 2026 | 45.1 | 18.6 | 45.0 | 100.0 | 21.1 | 40.3 | 0.0 |
| May 6, 2026 | 45.1 | 18.6 | 45.0 | 100.0 | 21.1 | 40.5 | -0.1 |
| May 5, 2026 | 45.2 | 18.6 | 45.0 | 100.0 | 21.1 | 40.6 | +0.1 |
| May 3, 2026 | 45.1 | 18.6 | 45.0 | 100.0 | 21.1 | 40.0 | -0.2 |
| May 2, 2026 | 45.3 | 18.6 | 45.0 | 100.0 | 21.1 | 41.3 | +0.1 |
TVTX — Pillar Breakdown
Quality
— 17.5/100 (25%)Travere Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 100.0/100 (20%)Travere Therapeutics, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 23.5/100 (15%)Travere Therapeutics, Inc. presents elevated risk with concerns around leverage or financial stability.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 42.4/100 (15%)Travere Therapeutics, Inc. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 45/100 (25%)Travere Therapeutics, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for TVTX.
Score Composition
Financial Data
More Stock Analysis
How is the TVTX UQS Score Calculated?
The UQS (Unified Quality Score) for Travere Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Travere Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Travere Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.